Avacta Share Discussion Threads

[jacktrax] 23/2/2024 09:38

Regarding Myles , if he was inside on a placing would he have spoke on X this morning, no . So this placing going to retail, no. Institutes yes

[jacktrax] 23/2/2024 09:35

The placing is inevitable, will it go to us retail or will it go to sticky hands , it's a cruel game this , ignore the noise , I'm holding

[fieldhouse] 23/2/2024 08:57

The share price is what it is !
Distorted by misinformation and rummer ! could go up--could go down !

[fieldhouse] 23/2/2024 08:55

Management are sticking with the last company information.
Believe or not !!

[amanitaangelicus] 23/2/2024 08:52

Missed the rise ... let.s see how genuine it is.

[pwhite73] 23/2/2024 08:52

Up 4.5% so far. Has that lying charlatan Aman claimed he dipped his toes it at 72p earlier this morning?

[atmysignal] 23/2/2024 08:51

Management have destroyed loyal shareholders by their ineptitude

[master investor] 23/2/2024 08:45

What a buying opportunity. The chart looks good for a reversal.

[amanitaangelicus] 23/2/2024 08:28

Wowza volume ... mmmm.

[amanitaangelicus] 23/2/2024 07:57

Yup, been saying it for eons.

[ohwhatfun] 23/2/2024 07:55

Aman

Thinking of the Convi.

It could be highly lucrative for those behind it to smash down the price floor.

They get that or 10% below the conversion day price.

If they were approached a second time still owed £44m, in this climate the demand could be brutal, forcing Avacta to the market which is equally brutal.

Not even an RNS saying “No known reason for the share price drop” which points to current negotiations for funding in play.

Good prospects have been destroyed in this current market. The willing cash is very thin on the ground.

[loglorry1] 23/2/2024 07:50

Myles desperate on Twitter. I guess he has same view on Ben's Creek and Tiripati Graphite his other two top picks I believe.

[vertizeasun] 23/2/2024 07:50

When do you buy Mr Rothschild?

I buy when there is blood on the streets.

[beatme1] 23/2/2024 07:48

Into the lows 60s I reckon

[ohwhatfun] 23/2/2024 07:38

I’m not short here, not about that.

I just want to know what is so special about something apparently abandoned in the US.

From business type databases the best date I can come up for Arisaph liquidating is March 2017.
Later that year Dr Michael Vincent (ex Arisaph) appears at Avacta. Avacta later do deals with Tufts. Dr Bachovin of tufts, was a co-founder of Arisaph.

Next up Avacta news re Tufts collaboration. Then this NEW method which Arisaph had, so clearly not new.

Then sold as groundbreaking on the AIM Merry-go-round.

I think Dr Vincent has since left the Avacta US team.

So why get so excited about a rebrand of a previously abandoned potential treatment.

Why was it ditched, Avacta must know, they did employ Arisaph staff.

[amanitaangelicus] 23/2/2024 07:30

Hindsight gals out in force. No rns as yet. Allowing the boyz to plan their manoeuvres? Myles or someone needs to put out some 'news'. Whatever.s happened has leaked. Pi.s should be told.Ps the story here is far from finished, especially if you believe the hype/ veracity of Smith s comments on the data so far. He is notoriously slow however in coming clean on stuff eg the LFT fiasco - he still hasnt given us a full explanation for that eventual debacle. I genuinely hope he s not been economical with the truth again. And before you argue about the long gone LFT stuff, it gave us a flavour of how he.ll spin things out, keep bad news at bay for as long as possible.Convi reset in full flow for me. Hope I.m very wrong. More of the convis? Please no!!GLA.

[blackhorse23] 23/2/2024 07:18

This stock is over, require more funding for their project

[the cronk] 23/2/2024 00:37

I managed a short early doors, shame IG wouldn't allow shorts a few weeks ago when I wanted to open one.

If it is a placing the price may be painful for holders in this market

[amanitaangelicus] 22/2/2024 22:18

A leak is clearly out there - and the price/ amount/ type.

[bones698] 22/2/2024 20:26

Still very early stage and not a promising past so no idea why it has such a high market cap given it has very little cash, probably sun 20m. Is years away with trials and the risks envilved in those.
For me I would bt be surprised to see this at 20p never mind 77p. Just don't see any real value or reason for a 240m mkt cap. There are companies with better prospects valued at a fraction of this. Tells me is been hyped to high heaven and now reality is kicking in.

[atmysignal] 22/2/2024 20:18

He's very good.

[ohwhatfun] 22/2/2024 19:41

The wording both are Fap based Avct have Ari 6000 and Ari 3996 (Arisaph)

For ARI-3996 to be a viable drug candidate, it will be essential to demonstrate that treatment with ARI-3996 produces significant antitumor effects with at least 10-fold less systemic toxicity than bortezomib.

Whilst on the topic I believe the Avacta Ceo said there is no Fap in healthy tissues, but in the Arisaph papers it states there is, which may be the reason behind the 10 fold requirement.

It looks like failed Arisaph trials repeated under Avacta in the UK.

So if I was a fund doing due diligence, I’d want to know why Arisaph ended trials.

As we know ava 6000 did not produce significant anti-tumour effects with the increased dose. As for 10 fold they don’t quote it.

Shasqi have shown their method can go 12 times and more of the normal Dox dose

[ohwhatfun] 22/2/2024 19:26

Log

Avacta tech is just a rehash of Arisaph tech (US) same origin, patent holder Tufts.
The details come from Arisaph comments 3996 version to proceed to phase 2. Some Arisaph staff came to Avacta. Note the Avacta Tufts deal.

The name Arisaph derives from Michael Jaharis a co founder. He was a founder of Kos pharma which was acquired making Michael worth $2 billion.

Arisaph disappeared, no phase 2, so I assume phase 1 didn’t produce the required data to support phase 2 and hence it was abandoned.

Then it all re-appeared under Avacta, who are pushing for the US, where it started.

It makes no sense, Arisaph had very wealthy backers but it was all ditched.

Hence the question around pure AIM spin. There must be a good reason why Arisaph set those progression parameters, perhaps it’s in FDA requirements.

Which is why I keep asking what the factor is Dox in healthy tissue v the tumour which will give the factor.

Shasqi gave theirs which is 80 fold.

It’s obviously relevant but Avacta don’t quote what it is.🤷‍♂️

[pwhite73] 22/2/2024 18:58

Aman - "The ramp queens like Tickboo et al have been vitriolic in their attacks on naysayers, but particularly myself"

You see that's just the point you haven't been a naysayer. You've been a naysayer when you've perfectly timed your sells and a yeasayer when you've perfectly timed your buys.

I'm what you call a naysayer but I have always had the utmost respect for tickboo and still do.